GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ind-Swift Laboratories Ltd (NSE:INDSWFTLAB) » Definitions » EV-to-EBITDA

Ind-Swift Laboratories (NSE:INDSWFTLAB) EV-to-EBITDA : 6.29 (As of Apr. 29, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Ind-Swift Laboratories EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ind-Swift Laboratories's enterprise value is ₹15,044 Mil. Ind-Swift Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹2,393 Mil. Therefore, Ind-Swift Laboratories's EV-to-EBITDA for today is 6.29.

The historical rank and industry rank for Ind-Swift Laboratories's EV-to-EBITDA or its related term are showing as below:

NSE:INDSWFTLAB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.45   Med: 6.96   Max: 407.88
Current: 6.29

During the past 13 years, the highest EV-to-EBITDA of Ind-Swift Laboratories was 407.88. The lowest was 0.45. And the median was 6.96.

NSE:INDSWFTLAB's EV-to-EBITDA is ranked better than
83.62% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.22 vs NSE:INDSWFTLAB: 6.29

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-29), Ind-Swift Laboratories's stock price is ₹124.95. Ind-Swift Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹7.360. Therefore, Ind-Swift Laboratories's PE Ratio for today is 16.98.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Ind-Swift Laboratories EV-to-EBITDA Historical Data

The historical data trend for Ind-Swift Laboratories's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ind-Swift Laboratories EV-to-EBITDA Chart

Ind-Swift Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.52 6.59 7.10 5.58 5.06

Ind-Swift Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 5.06 2.17 5.37 2.57

Competitive Comparison of Ind-Swift Laboratories's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ind-Swift Laboratories's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ind-Swift Laboratories's EV-to-EBITDA falls into.



Ind-Swift Laboratories EV-to-EBITDA Calculation

Ind-Swift Laboratories's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=15043.970/2392.62
=6.29

Ind-Swift Laboratories's current Enterprise Value is ₹15,044 Mil.
Ind-Swift Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,393 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ind-Swift Laboratories  (NSE:INDSWFTLAB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ind-Swift Laboratories's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=124.95/7.360
=16.98

Ind-Swift Laboratories's share price for today is ₹124.95.
Ind-Swift Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹7.360.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Ind-Swift Laboratories EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ind-Swift Laboratories's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ind-Swift Laboratories (NSE:INDSWFTLAB) Business Description

Traded in Other Exchanges
Address
SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh, PB, IND, 160 101
Ind-Swift Laboratories Ltd is engaged in the business of active pharmaceutical ingredients (API). The company caters to diverse therapeutic segments namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitor. Geographically, it derives a majority of revenue from Outside India.

Ind-Swift Laboratories (NSE:INDSWFTLAB) Headlines

No Headlines